{"schema_version":"secwatch.filing_event.v1","accession":"0001723128-22-000037","form_type":"8-K","ticker":"AMRX","cik":"0001723128","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2022-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.886704+00:00","generated_at":"2026-06-22T07:09:32.109283+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Amneal Q3 2022 revenue $546M (+3.2% YoY), adj. EBITDA $126M, adj. EPS $0.14","bullets":["Net revenue $546M, up 3.2% from $529M in Q3 2021; GAAP net loss $3M (diluted EPS $(0.02)).","Adjusted EBITDA $126M, down 5.1% YoY; adjusted diluted EPS $0.14 vs $0.21 in prior year.","Full-year 2022 outlook maintained; management cites new product approvals and biosimilar launch momentum.","AvKARE delivered double-digit growth; Generics and Specialty segments remained consistent."],"urls":{"canonical":"https://secwatch.observer/filing/0001723128-22-000037","json":"https://secwatch.observer/filing/0001723128-22-000037.json","markdown":"https://secwatch.observer/filing/0001723128-22-000037.md","text":"https://secwatch.observer/filing/0001723128-22-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1723128/000172312822000037/0001723128-22-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1723128/000172312822000037/amrx-20221104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T07:09:32.109283+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"29ab54dd691cf7e477aeca7f33bc2780440cbceb","claim":"Amneal Pharmaceuticals, Inc. reported the third quarter ended September 30, 2022 results: revenue $546 million, net income $3 million, EPS $(0.02). Guidance reaffirmed.","evidence_excerpt":"the information furnished pursuant to Item 2.02 of this report. --- EX-99.1 (EX-99.1) --- AMNEAL REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS ‒ Q3 2022 Net Revenue of $546 million; GAAP Net Loss of $3 million; Diluted Loss per Share of $(0.02) ‒ ‒ Adjusted EBITDA (1) of $126 million; Adjusted Diluted EPS (1) of $0.14 ‒ ‒ Maintaining 2022 Full Year Outlook","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1723128/000172312822000037/0001723128-22-000037-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$546 million"},{"label":"Net income","value":"$3 million"},{"label":"EPS","value":"$(0.02)"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}